This study is the first clinically validated noninvasive solution for mapping the TAN infiltration status in gastric cancer. EnmlbaRB effectively stratified the patients based on survival outcomes and immunotherapy responsiveness. This paradigm empowers clinicians to personalize therapeutic sequencing based on evolving TAN biology, thereby addressing the critical need for adaptive treatment strategies for advanced gastric cancer management.
Zheng et al. (Sun,) studied this question.